glp-1 mcas A newly published case series reports that receptor agonists (like semaglutide and tirzepatide) may significantly improve symptoms in patients with mast cell activation syndrome (MCAS), even in those without diabetes or GLP-1: Genetic Variants Related to

Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults

Rambhia has published numerous peer-reviewed articles in leading journals, including the Journal of the American Academy of Dermatology, Lasers in Surgery and Medicine, Dermatologic Surgery, International Journal of Dermatology, Journal of Clinical and Aesthetic Dermatology, Melanoma Research, and the International Journal of Clinical Oncology

Safe and Effective: L-carnitine is known for its safety profile, making it a reliable choice for individuals aiming for optimal recovery after workout

Our results are generally consistent in direction and magnitude with the existing clinical research, including trials showing reduced heavy alcohol consumption among those with obesity,14 reduced drinking in an experimental bar setting,12 and pharmacoepidemiological analyses showing that GLP-1 receptor agonists are associated with lower incidence and recurrence of alcohol use disorder,2 reduced need for tobacco use related care,5 lower incidence and relapse of cannabis use disorder,4 and reduced risk of opioid overdose in patients with opioid use disorders.8 Our results show that among people with a pre-existing SUD, GLP-1 receptor agonist use was associated with a reduced risk of several adverse clinical outcomes (SUD related emergency department visits, hospital admission, and mortality, drug overdose, and suicidal attempt or ideation)